

PATENT COOPERATION TREATY

TRANSLATION

From the
INTERNATIONAL SEARCHING AUTHORITY

PCT

WRITTEN OPINION OF THE
INTERNATIONAL SEARCHING AUTHORITY

(PCT Rule 43bis.1)

To:

Date of mailing (day/month/year)	26.05.2015
-------------------------------------	-------------------

Applicant's or agent's file reference 15-0019-PCT	FOR FURTHER ACTION See paragraph 2 below
---	--

International application No. PCT/JP2015/055053	International filing date (day/month/year) 23.02.2015	Priority date (day/month/year) 17.03.2014
---	---	---

International Patent Classification (IPC) or both national classification and IPC
A61F2/966 (2013.01) i

Applicant
TERUMO KABUSHIKI KAISHA

1. This opinion contains indications relating to the following items:

- Box No. I Basis of the opinion
- Box No. II Priority
- Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- Box No. IV Lack of unity of invention
- Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- Box No. VI Certain documents cited
- Box No. VII Certain defects in the international application
- Box No. VIII Certain observations on the international application

2. **FURTHER ACTION**

If a demand for international preliminary examination is made, this opinion will be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA") except that this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notified the International Bureau under Rule 66.1bis(b) that written opinions of this International Searching Authority will not be so considered.

If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later.

For further options, see Form PCT/ISA/220.

Name and mailing address of the ISA/JP	Date of completion of this opinion	Authorized officer
Facsimile No.		Telephone No.

WRITTEN OPINION OF THE
INTERNATIONAL SEARCHING AUTHORITY

International application No.

PCT/JP2015/055053

Box No. I Basis of this opinion

1. With regard to the **language**, this opinion has been established on the basis of:
 - the international application in the language in which it was filed
 - a translation of the international application into _____, which is the language of a translation furnished for the purposes of international search (Rules 12.3(a) and 23.1(b)).
2. This opinion has been established taking into account the **rectification of an obvious mistake** authorized by or notified to this Authority under Rule 91 (Rule 43*bis*.1(a))
3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, this opinion has been established on the basis of a sequence listing filed or furnished:
 - a. (means)
 - on paper
 - in electronic form
 - b. (time)
 - in the international application as filed
 - together with the international application in electronic form
 - subsequently to this Authority for the purposes of search
4. In addition, in the case that more than one version or copy of a sequence listing has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
5. Additional comments:

**WRITTEN OPINION OF THE
INTERNATIONAL SEARCHING AUTHORITY**

International application No. PCT/JP2015/055053
--

Box No. V	Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
------------------	---

1. Statement			
Novelty (N)		Claims <u>1-7</u>	YES
		Claims _____	NO
Inventive step (IS)		Claims <u>1-7</u>	YES
		Claims _____	NO
Industrial applicability (IA)		Claims <u>1-7</u>	YES
		Claims _____	NO

2. Citations and explanations:	
--------------------------------	--

Document 1: JP 2013-183918 A (TERUMO CORP.) 19 September 2013, entire text, all drawings (Family: none)

Document 2: JP 2010-533014 A (ANGIOMED GMBH & CO. MEDIZINTECHNIK KG.) 21 October 2010, paragraphs [0060]-[0097], fig. 2-10 & US 2010/0174290 A1 & WO 2009/007432 A1 & EP 2164430 A1

Document 3: JP 2001-029478 A (TERUMO CORP.) 06 February 2001, entire text, all drawings (Family: none)

Document 4: US 2010/0087906 A1 (ANGIOMED GMBH & CO. MEDIZINTECHNIK AG) 08 April 2010, paragraphs [0096], [0097], fig. 14 & WO 2006/133960 A1 & EP 1890644 A1

The invention as in claims 1-7 is not disclosed in any of the documents cited in the ISR and would not be obvious to a person skilled in the art.

Documents 1-4 do not disclose the feature of having "an extension preventing shaft fixed at one end to a

WRITTEN OPINION OF THE
INTERNATIONAL SEARCHING AUTHORITY

International application No.

PCT/JP2015/055053

Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

tubular body to prevent the extension of the tubular body in the distal-end direction"; and "a second towing part that is provided on the proximal end part of a stent delivery system and is coupled with the proximal end part of the extension preventing shaft, and that moves the extension preventing shaft in the proximal end direction."

The invention as in claims 1-7, as a result of the aforementioned feature, exhibits the advantageous effect wherein, "since an extension preventing shaft is provided for preventing the extension of the tubular body in the distal-end direction, the force from the tubular body, which has been slackened in the proximal end direction, trying to extend again in the distal end direction can be received by the extension preventing shaft, the tubular body is prevented from extending in the distal end direction when a stent is released, and the stent can be expanded and set in the appropriate state while preventing the phenomenon of the stent length becoming short."